When a project is under time pressure, independent ethical review can start to look like an obstacle rather than a safeguard, a box to tick as quickly as possible, or in some cases, to skip altogether. The saving feels real and immediate. The costs of getting it wrong tend to show up later, and they tend to be larger.
The saving is visible; the cost is deferred
Cutting corners on review can shave weeks off a start date. What it doesn't do is make the underlying ethical questions disappear, it just moves them to a point in the study where they are far more expensive to answer. A consent process that should have been questioned at design stage becomes a recruitment problem six months in. A data handling gap that should have been caught early becomes a breach investigation later.
A 2024 analysis of 207 retracted orthopaedic research articles found the mean gap between publication and retraction was 32.1 months, over two and a half years. Whatever the underlying problem, it doesn't surface, get investigated, and result in a retraction quickly. It sits there, cited and built on, until it does.
The cheapest time to answer an ethical question is before the study begins. The most expensive time is after the data has been collected.
Where the costs really land
Skipping review doesn't eliminate the ethical questions, it simply relocates them to stages where addressing them is far more disruptive. The bill tends to arrive at publication first: journals and funders increasingly expect evidence of independent ethical oversight, and without it, months of work can stall before results are ever shared. In that same analysis of retracted orthopaedic articles, "no approval from an ethics board" was recorded as the specific reason for retraction in 17 of the 207 cases, on a par with fraud (25 cases) and ahead of author's-choice withdrawals or copyright disputes. It shows up again in partnerships, where collaborators and institutional partners treat independent review as a basic marker of credibility, particularly for organisations outside the NHS or academic sectors, and in recruitment, where participants are more willing to trust a process that has been checked by someone other than the people running it. A gap in data handling that would have been caught in review becomes a potential breach investigation once the study is live rather than a fixable design note beforehand. And underneath all of it sits reputation: the long-term cost of a study that is publicly questioned or retracted far exceeds the short-term cost of proper review, and as the retraction figures above show, missing ethics approval isn't a minor technicality reviewers wave through after the fact; it's a recorded, citable reason a paper gets pulled.
Independent review as risk management, not red tape
The most useful way to think about ethical review isn't as a regulatory hurdle but as a second pair of expert eyes, one that catches the things a close, invested study team is least likely to see in their own design. That's not a cost. It's one of the cheapest forms of risk management available, especially set against the cost of a study that runs into trouble after data collection has already begun, or, as the retraction data suggests, years after publication.
Building it in, not bolting it on
The studies that get the most value from ethical review are the ones that involve it early, while a design choice is still just an idea on a whiteboard, not a commitment that's expensive to unwind. Treated that way, review stops being something that happens to a study and becomes part of how a good study gets built.
